The global cell and gene therapy for oncology market size was estimated at USD 14.82 billion in 2025 and is predicted to increase from USD 18.48 billion in 2026 to approximately USD 134.53 billion by 2035, expanding at a CAGR of 24.68% from 2026 to 2035. The market is expanding rapidly due to increasing cancer cases and rising demand for personalized and targeted cancer treatments. Advancements in CAR-T therapy, gene editing technologies, and growing investments in oncology research are further supporting market growth.
Cell and gene therapy for oncology is an advanced cancer treatment approach that uses modified cells or genetic material to target, destroy, or prevent cancer cells more effectively. The cell and gene therapy for oncology market is growing rapidly due to the increasing prevalence of cancer and the rising demand for personalized and targeted treatment options. Advancements in CAR-T cell therapy, gene editing technologies, and immunotherapy are improving treatment outcomes and expanding clinical applications. In addition, growing investments in oncology research, supportive regulatory initiatives, and increasing clinical trials are further accelerating market expansion globally.
Artificial intelligence is transforming the market by accelerating drug discovery, improving patient selection, and enhancing treatment precision. AI-powered data analysis helps identify genetic targets, optimize clinical trials, and predict therapy responses more effectively. This supports faster development of personalized cancer therapies while reducing research costs and improving overall treatment outcomes.
Growing Adoption of Personalized Cancer Therapies
Increasing focus on precision medicine is driving demand for personalized cell and gene therapies tailored to individual patient profiles. This trend is improving treatment effectiveness, reducing side effects, and expanding the use of advanced oncology therapies across multiple cancer indications.
Advancements in Gene Editing and CAR-T Technologies
Continuous innovations in CRISPR gene editing, CAR-T cell therapy, and next-generation immunotherapies are enhancing treatment accuracy and clinical outcomes. These advancements are expected to accelerate product development and create new opportunities in the oncology treatment landscape.
Rising Investments and Expanding Clinical Trials
Growing investments from pharmaceutical companies, biotechnology firms, and government organizations are supporting large-scale research and clinical trials. This is expected to strengthen commercialization efforts, improve therapy accessibility, and drive long-term market growth globally.
| Table | Scope |
| Market Size in 2026 | USD 18.48 Billion |
| Projected Market Size in 2035 | USD 134.53 Billion |
| CAGR (2026 - 2035) | 24.68% |
| Leading Region | North America by 46% |
| Historical Data | 2020 - 2023 |
| Base Year | 2025 |
| Forecast Period | 2026 - 2035 |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By Therapy Type, By Cancer Type, By Therapy Source, By Delivery Vector, By Application, By End User, By Manufacturing Type, By Route of Administration, By Region |
| Top Key Players | Amgen Inc., Novartis AG, Gilead Sciences, Inc., bluebird bio, Inc., Bristol Myers Squibb Company, Legend Biotech, JW Therapeutics |
| Segment | Share 2025 (%) |
| Cell Therapy | 68% |
| Gene Therapy | 32% |
The Cell Therapy Segment Dominated the Cell and Gene Therapy for Oncology Market in 2025
The cell therapy segment held a dominant share of 68% in 2025 due to the strong adoption of CAR-T cell therapies and their proven effectiveness in treating various hematologic cancers. Increasing regulatory approvals, expanding clinical applications, and growing investment in personalized cancer treatments further supported segment growth. In addition, advancements in cell engineering technologies and rising demand for targeted immunotherapies strengthened the market position of cell-based oncology therapies.
The gene therapy segment held the second-largest share of 27% in 2025 and is expected to grow at the fastest CAGR in the cell and gene therapy for oncology market during the forecast period due to its strong potential to directly modify or correct cancer-causing genetic mutations. Increasing clinical trials, growing success in treating rare and solid tumors, and rapid advancements in gene-editing technologies are driving adoption. However, higher development costs and regulatory complexities slightly limit faster commercialization compared to established cell therapy approaches.
| Segment | Share 2025 (%) |
| Hematological Malignancies | 64% |
| Solid Tumors | 36% |
The Hematological Malignancies Segment Led the Market in 2025 with the Largest Share
The hematological malignancies segment led the cell and gene therapy for oncology market with a share of 64% in 2025 due to the high success rate of CAR-T and other cell-based therapies in blood cancers such as leukemia, lymphoma, and multiple myeloma. These cancers are more accessible for treatment compared to solid tumors, allowing better therapy delivery and outcomes. Strong clinical approvals and expanding use of targeted immunotherapies further reinforced segment dominance.
The solid tumors segment held the second-largest share of 36% in 2025 and is expected to grow at the fastest CAGR in the cell and gene therapy for oncology market during the forecast period due to the high global burden oc cancers such as breast, lung, and colorectal cancer. Increasing research in overcoming tumor microenvironment barriers, along with advancements in gene editing and engineered cell therapies, is improving treatment potential. However, complex tumor structures and delivery challenges have limited faster adoption compared to hematological malignancies.
| Segment | Share 2025 (%) |
| Hospitals | 38% |
| Cancer Treatment Centers | 27% |
| Academic & Research Institutes | 14% |
| Biotechnology & Pharmaceutical Companies | 16% |
| Specialty Clinics | 5% |
The Hospitals Segment Led the Market in 2025 with the Largest Share
The hospitals segment held a dominant share of 38% of the cell and gene therapy for oncology market in 2025 due to the availability of advanced infrastructure, specialized oncology departments, and skilled healthcare professionals required for complex therapies like CAR-T and gene therapy. Hospitals also handle a high volume of cancer patients and have better access to clinical trials and regulatory approvals, making them the primary centers for administering and managing advanced cancer treatment.
The cancer treatment centers segment held the second-largest share of 27% in 2025 due to their strong specialization in oncology care and access to advanced therapeutic technologies. These centers offer focused expertise, shorter treatment pathways, and better patient monitoring for complex therapies like CAR-T and gene therapy. However, the limited infrastructure compared to large hospitals slightly restricts their overall patient handling capacity.
The biotechnology & pharmaceutical companies segment held 16% share in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period due to their strong focus on R&D, pipeline expansion, and strategic collaborations for advanced therapies. Increasing investments in gene editing, CAR-T development, and clinical trials for commercial innovations. Additionally, rising demand for commercial-scale manufacturing and faster regulatory approvals is further driving segment growth.
The academic & research Institutes segment held a 14% of cell and gene therapy for oncology market share due to increasing focus on early-stage research, innovation, and discovery of novel cancer treatment approaches. Strong government funding, collaborations with biotech firms, and expanding clinical trial activities are supporting growth. These institutes play a key role in developing advanced gene editing techniques and understanding cancer biology, driving long-term therapies advancements.
| Segment | Share 2025 (%) |
| In-House Manufacturing | 58% |
| Contract Manufacturing | 42% |
The In-House Manufacturing Segment Led the Market in 2025 with the Largest Share
The in-house manufacturing segment dominated the cell and gene therapy for oncology market with a share of 58% in 2025 due to companies' need for strict quality control, process consistency, and protection of sensitive intellectual property. Producing therapies internally helps reduce dependency on third-party CDMOs, ensures faster production timelines, and supports complex personalized treatments like CAR-T. Additionally, high initial investments are justified by better scalability, regulatory compliance, and long-term cost efficiency.
The contract manufacturing segment held the second-largest share of 42% in 2025 and is expected to grow at the fastest CAGR in the cell and gene therapy for oncology market during the forecast period due to increasing outsourcing by biotech and pharmaceutical companies to specialized CDMOs. These providers offer advanced manufacturing capabilities, scalability, and regulatory expertise, reducing time-to-market and capital investments. However, dependence on third parties and concerns over process control and confidentiality slightly limit broader adoption compared to in-house manufacturing.
North America dominated the cell and gene therapy for oncology market with a share of 46% in 2025 due to its advanced healthcare infrastructure, strong presence of leading biotech and pharmaceutical companies, and high investment in R&D. Early regulatory approvals, widespread adoption of CAR-T therapies, and robust clinical trials activity further support growth. Additionally, favorable reimbursement policies and increasing cancer prevalence strengthen the region’s leadership in advanced oncology treatments.
U.S. Market Trends
The U.S. leads the cell and gene therapy for oncology market due to strong R&D investments, presence of major biotech and pharmaceutical companies, and rapid adoption of advanced therapies like CAR-T. Supportive FDA approvals, a well-established clinical trials ecosystem, and high cancer prevalence further drive growth. Additionally, strong funding, innovative startups, and advanced healthcare infrastructure reinforced the U.S. dominance in this market.
Asia Pacific captured 21% share in 2025 and is anticipated to grow at the fastest CAGR in the cell and gene therapy for oncology market due to rising cancer prevalence, improving healthcare infrastructure, and increasing adoption of advanced therapies. Growing government support, expanding clinical trials, and rising investments from global biotech firms are further accelerating growth. Additionally, increasing patient awareness and improving access to innovative treatments are boosting regional market expansion.
India Market Trends
India is expected to grow at the fastest CAGR in the cell and gene therapy for oncology market due to its large patient pool, rising cancer burden, and improving healthcare infrastructure. Increasing government support for biotechnology, growing clinical trials activity, and expanding investments from global pharma companies are accelerating adoption. Additionally, the rising affordability of advanced therapies and growing awareness of personalized medicine are further boosting market growth.
R&D
Clinical Trials
Patient Support and Services
| Companies | Headqaurters | Offerings |
| Amgen Inc. | California, U.S. | Develops CAR-T and bispecific T-cell engager therapies (e.g., Blincyto) and advanced immuno-oncology and cell therapy pipelines for blood cancers. |
| Novartis AG | Basel, Switzerland | Pioneer in CAR-T therapy (Kymriah) for leukemia and lymphoma, focusing on personalized cell-based cancer treatments. |
| Gilead Sciences, Inc. | California, U.S. | Through Kite Pharma offers CAR-T therapies (Yescarta, Tecartus) for lymphoma and multiple myeloma. |
| bluebird bio, Inc. | Massachusetts, U.S. | Specializes in gene and cell therapies for hematologic cancers and genetic diseases using lentiviral gene modification. |
| Bristol Myers Squibb Company | New York, U.S. | Provides CAR-T therapies (Breyanzi, Abecma) and invests heavily in next-generation oncology cell therapies. |
| Legend Biotech | Somerset, New Jersey, U.S. | Focuses on CAR-T therapy (Carvykti) for multiple myeloma in collaboration with Johnson & Johnson. |
| JW Therapeutics | Shanghai, China | Develops CAR-T cell therapies for hematologic malignancies, including relapsed/refractory lymphomas. |
Strengths
Weaknesses
Opportunities
Threats
By Therapy Type
By Cancer Type
By Therapy Source
By Delivery Vector
By Application
By End User
By Manufacturing Type
By Route of Administration
By Region
Principal Consultant
Rohan Patil is a seasoned market research professional with over 5+ years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.
Learn more about Rohan Patil
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
+1 804-441-9344
